Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
29 - Use of Non-A/Non-B Botulinum Toxins
from Section II - Botulinum Toxin Therapy
Published online by Cambridge University Press: 31 May 2018
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 137 - 138Publisher: Cambridge University PressPrint publication year: 2018
References
Anderson, J, Williams, PT, Katos, AM, et al. 2009. Botulinum toxins. In Gupta, RC, ed., Handbook of Toxicology of Chemical Warfare Agents. Amsterdam: Elsevier BV: 407–432.Google Scholar
Chen, R, Karp, BI, Hallett, M. 1998. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology 51:1494–1496.CrossRefGoogle ScholarPubMed
Coffield, JA, Bakry, N, Zhang, RD, et al. 1997. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J Pharmacol Exp Ther 280:1489–1498.Google Scholar
Eleopra, R, Tugnoli, V, Rossetto, O, et al. 1997. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 224: 91–94.CrossRefGoogle Scholar
Eleopra, R, Tugnoli, V, Rossetto, O, et al. 1998. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256: 135–138.CrossRefGoogle Scholar
Eleopra, R, Tugnoli, V, Quatrale, R, et al. 2002. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting. Clin Neurophysiol 113: 1258–1264.CrossRefGoogle Scholar
Eleopra, R, Tugnoli, V, Quatrale, R, et al. 2004. Different types of botulinum toxin in humans. Mov Disord 19 (Suppl. 8):S53–S59.CrossRefGoogle ScholarPubMed
Eleopra, R, Tugnoli, V, Quatrale, R, et al. 2006. Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res 9:127–131.CrossRefGoogle ScholarPubMed
Eleopra, R, Montecucco, C, Devigili, G, et al. 2013. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Clin Neurophysiol 124: 999–1004.CrossRefGoogle ScholarPubMed
Greene, PE, Fahn, S. 1993. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 8:479–483.CrossRefGoogle ScholarPubMed
Greene, PE, Fahn, S. 1996. Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 11:181–184.CrossRefGoogle ScholarPubMed
Jankovic, J. 2004. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiat 75:951–957.CrossRefGoogle ScholarPubMed
Johnson, EA, Montecucco, C. 2008. Botulism. In: Engel, AG, ed., Neuromuscular Junction Disorders: Handbook of Clinical Neurology. Amsterdam: Elsevier: 333–368.CrossRefGoogle Scholar
Ludlow, CL, Hallett, M, Rhew, K, et al. 1992. Therapeutic use of type F botulinum toxin. N Engl J Med 326:349–350.Google ScholarPubMed
Mezaki, T, Kaji, R, Brin, MF, et al. 1999. Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial. Mov Disord 14:1017–1020.3.0.CO;2-3>CrossRefGoogle Scholar
Rossetto, O, Pirazzini, M, Montecucco, C. 2014. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature 12:535–549.Google ScholarPubMed
Smith, LD, Sugiyama, H. 1988. Botulism: The Organism, its Toxins, the Disease. Springfield, IL: C.C. Thomas Publ.Google Scholar